Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients.

To investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type).,We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status.,Thirty-seven (37 of 116; 31.9%) BRCA1/2 mutations were identified (BRCA1: 30; BRCA2: 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5 of 37; 13.5%). Twenty-five patients had BRCA1/2 variants of uncertain significance (VUSs; 25 of 116; 21.6%). Personal histories of breast cancer were observed in 48.6% (18 of 37) of patients with BRCA1/2 mutation, 16.0% (4 of 25) of patients with BRCA1/2 VUS, and 7.4% (4 of 54) of patients with BRCA wild type (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p = 0.005). No significant differences were detected in PFS, OS or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p = 0.772, 0.459, and 0.898, respectively).,Patients with BRCA1/2 mutation had longer OS than those with BRCA1/2 wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.